BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zen-Bio, Inc. Awarded $961,000 Grant From National Institutes of Health (NIH); Proceeds To Fund The Development Of A Human Omental Adipocyte (Fat) Cell System Useful In The Discovery Of The Next Generation Cures And Diagnostic Tools For Obesity Related Diseases


10/19/2005 5:12:28 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sept. 21, 2005--Zen-Bio, Inc, a private closely held biotechnology company, today announced that it was awarded a 24 month $961,578 Phase II SBIR grant from the National Institutes of Health. The phase II application was awarded after the successful completion of Zen-Bio's $100,000 NIH Phase I award. The phase II grant was favorably reviewed by the NIH for both scientific merit and business strategy. The grant will be used to fund the development and characterization of a human omental adipocyte cell system. "The human omental cell system is a novel research tool invaluable to human metabolic disease researchers," states Dr. Renee Lea-Currie, Zen- Bio's Director of Cell Biology and the grant's Principal Investigator. She went on to state, "Customers will be able to use our human cell system to evaluate potential new drugs and therapies as well as elucidate some of the basic functions of this highly metabolically active endocrine organ."

Read at BioSpace.com

   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES